Inventiva (NASDAQ:IVA) Shares Up 6.8% – Time to Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares were up 6.8% during trading on Tuesday . The stock traded as high as $4.10 and last traded at $4.1640. Approximately 1,025,597 shares traded hands during mid-day trading, an increase of 75% from the average session volume of 587,467 shares. The stock had previously closed at $3.90.

Analysts Set New Price Targets

IVA has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Wall Street Zen downgraded shares of Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Truist Financial began coverage on shares of Inventiva in a research note on Thursday, March 19th. They issued a “buy” rating and a $13.00 price objective on the stock. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $16.56.

Inventiva Stock Performance

The stock’s 50 day moving average price is $4.50 and its 200 day moving average price is $5.32.

Institutional Investors Weigh In On Inventiva

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Creative Planning bought a new position in Inventiva in the 2nd quarter valued at about $32,000. Virtu Financial LLC bought a new position in Inventiva in the 4th quarter valued at approximately $60,000. XTX Topco Ltd bought a new stake in shares of Inventiva during the fourth quarter worth $84,000. Cerity Partners LLC acquired a new position in shares of Inventiva during the fourth quarter worth $93,000. Finally, NewEdge Advisors LLC bought a new position in shares of Inventiva in the 3rd quarter valued at $116,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.